We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Gastroenterology

Rapid Skeletal Muscle Loss in Cirrhosis: Predictors, Outcomes, and Implications for Clinical Management

MedXY Editorial Team•Aug 4, 2026•Gastroenterology
cirrhosisSarcopeniaMELD-Namuscle losswaitlist mortality

Highlight

  • Median annual skeletal muscle loss in patients with cirrhosis awaiting liver transplantation is approximately 1.6%.

  • Rapid muscle loss (RML), defined as the worst quartile of muscle loss (< -7.4% per year), predicts significantly higher waitlist mortality independent of MELD-Na score.

  • Ascites and higher MELD-Na scores independently associate with increased risk of RML.

  • Understanding the rate of muscle loss and its predictors informs prognostication and potential interventions targeting sarcopenia in cirrhosis.

Study Background

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Distinct Gut Microbiome Signatures Predict Short-term Hospitalisation Risk in Cirrhosis: Insights from a Global Metagenomic StudyThis multinational study reveals that specific gut microbiome profiles significantly correlate with 90-day hospitalisation risk in cirrhosis, enhancing prognostic accuracy beyond clinical features alone.Sep 27, 2026Epidemiology and Outcomes of CRRT in Critically Ill Cirrhosis Patients: Insights from the HRS-HARMONY and CRRTnet RegistriesThis study analyzes the epidemiology, treatment processes, and outcomes of critically ill cirrhosis patients undergoing continuous renal replacement therapy, highlighting high mortality rates, anticoagulation practices, and implications ofSep 24, 2026Steatotic Liver Disease Risk Scores for Predicting Cirrhosis and Hepatocellular Carcinoma: A Comprehensive Clinical ReviewThis review assesses the clinical utility of steatotic liver disease risk scores in predicting cirrhosis and hepatocellular carcinoma, highlighting the superior performance of the SAFE score for cirrhosis and challenges in HCC risk predictiSep 24, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing &amp; care
How often should a couple have sex?
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Sequential Lactulose and TeleTai-Chi to Prevent Falls in Cirrhosis: Insights from the LiveSMART Trial
The LiveSMART trial demonstrates that lactulose, with or without sequential TeleTai-Chi, significantly reduces fall risk and related harms in cirrhotic patients without prior overt hepatic encephalopathy.
Sep 21, 2026
Dissecting Gut-Vascular Barrier Failures: Macrophage Dysfunction Drives Bacterial Translocation in CirrhosisThis study elucidates how intestinal blood vessel-associated macrophage dysfunction contributes to gut-vascular barrier breakdown and bacterial translocation in cirrhosis, revealing novel mechanisms that underlie systemic infection risks inSep 21, 2026
Comparative Effectiveness of Carvedilol Versus Other Nonselective β-Blockers in Cirrhosis: A Clinical ReviewCarvedilol demonstrates superior effectiveness over nadolol and propranolol in reducing portal hypertension and preventing cirrhosis decompensation events, with emerging evidence supporting its preferential use in both compensated and decomAug 27, 2026